Harvard Bioscience, Inc.HBIONASDAQ
Loading
EBITDA Margin Over TimeExpanding
Percentile Rank50
3Y CAGR+94.6%
5Y CAGR+3.9%
Year-over-Year Change
EBITDA as a percentage of revenue
3Y CAGR
+94.6%/yr
vs -34.2%/yr prior
5Y CAGR
+3.9%/yr
Recent acceleration
Acceleration
+128.8pp
Accelerating
Percentile
P50
Within normal range
vs 5Y Ago
1.2x
Modest growth
Streak
1 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | 6.14% | +492.3% |
| 2024 | -1.57% | -121.9% |
| 2023 | 7.16% | +759.2% |
| 2022 | 0.83% | -89.0% |
| 2021 | 7.59% | +49.8% |
| 2020 | 5.06% | -23.0% |
| 2019 | 6.58% | +48.1% |
| 2018 | 4.44% | +4579.3% |
| 2017 | -0.10% | -105.8% |
| 2016 | 1.72% | - |